Autologous muscle derived stem cell therapy - Cook MyoSite

Drug Profile

Autologous muscle derived stem cell therapy - Cook MyoSite

Alternative Names: AMDC - Cook MyoSite; AMDC-USR; Autologous muscle derived cells - Cook MyoSite; Autologous muscle derived stem cells - Cook MyoSite; CMI-AMDC

Latest Information Update: 14 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cook MyoSite
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Stress incontinence
  • Phase II Bladder dysfunction
  • Phase I/II Faecal incontinence
  • Discontinued Ischaemic heart disorders

Most Recent Events

  • 12 Apr 2017 Cook MyoSite in collaboration with Quintiles plans a phase III trial for Stress incontinence (NCT03104517)
  • 29 Jan 2017 Cook MyoSite completes a phase III trial in Stress incontinence in United Kingdom, Canada and Germany (NCT01382602)
  • 01 Dec 2014 Cook initiates enrolment in a phase I/II trial for Stress incontinence in USA (NCT02291432)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top